Private Equity

PE Fund Investments

Biopharma co. PlasmaGen raises Rs.225-Cr from Artlan Investments, others

YourStory  

Bengaluru-headquartered biopharma company PlasmaGen Biosciences has raised INR 225 crore from UK-based Artian Investments, well known public markets investor Ashish Kacholia, pharma industry entrepreneurs Anurag Bagaria, Dushyant Patel, and other high-net worth individuals. The round also saw participation from returning investors Eight Roads Ventures and F-Prime Capital. PlasmaGen makes life-saving drugs such as albumin, intravenous immunoglobulin, rabies immunoglobulin, hepatitis B immunoglobulin and RhD immunoglobulin. It claims to work with a network of 5000 physicians and hospitals across India. The company will use the fresh capital for international expansion, product development, and working capital requirements. Founded in 2010 by Vinod Nahar, PlasmaGen has raised INR 400 crore across multiple rounds. The company had last raised USD 6.9 million in a Series B round of funding in September 2022 at a valuation of USD 43.6 million from Eight Roads Ventures.